TY - JOUR
KW - Animals
KW - Antineoplastic Agents
KW - Breast Neoplasms
KW - Cells, Cultured
KW - Drug Screening Assays, Antitumor
KW - Female
KW - Genetic Heterogeneity
KW - Humans
KW - Mice
KW - Mice, Nude
KW - organoids
KW - Precision Medicine
KW - Tissue Banks
KW - basal
KW - biobank
KW - Breast cancer
KW - luminal
KW - organoids
KW - Precision Medicine
KW - triple negative
AU - Norman Sachs
AU - Joep de Ligt
AU - Oded Kopper
AU - Ewa Gogola
AU - Gergana Bounova
AU - Fleur Weeber
AU - Anjali Vanita Balgobind
AU - Karin Wind
AU - Ana Gracanin
AU - Harry Begthel
AU - Jeroen Korving
AU - Ruben van Boxtel
AU - Alexandra Alves Duarte
AU - Daphne Lelieveld
AU - Arne van Hoeck
AU - Robert Frans Ernst
AU - Francis Blokzijl
AU - Isaac Johannes Nijman
AU - Marlous Hoogstraat
AU - Marieke van de Ven
AU - David Anthony Egan
AU - Vittoria Zinzalla
AU - Jurgen Moll
AU - Sylvia Fernandez Boj
AU - Emile Eugene Voest
AU - Lodewyk Wessels
AU - Paul Joannes van Diest
AU - Sven Rottenberg
AU - Robert Gerhardus Jacob Vries
AU - Edwin Cuppen
AU - Hans Clevers
AB - Breast cancer (BC) comprises multiple distinct subtypes that differ genetically, pathologically, and clinically. Here, we describe a robust protocol for long-term culturing of human mammary epithelial organoids. Using this protocol, >100 primary and metastatic BC organoid lines were generated, broadly recapitulating the diversity of the disease. BC organoid morphologies typically matched the histopathology, hormone receptor status, and HER2 status of the original tumor. DNA copy number variations as well as sequence changes were consistent within tumor-organoid pairs and largely retained even after extended passaging. BC organoids furthermore populated all major gene-expression-based classification groups and allowed in vitro drug screens that were consistent with in vivo xeno-transplantations and patient response. This study describes a representative collection of well-characterized BC organoids available for cancer research and drug development, as well as a strategy to assess in vitro drug response in a personalized fashion.
BT - Cell
DA - 2018-01-11
DO - 10.1016/j.cell.2017.11.010
IS - 1-2
LA - eng
N2 - Breast cancer (BC) comprises multiple distinct subtypes that differ genetically, pathologically, and clinically. Here, we describe a robust protocol for long-term culturing of human mammary epithelial organoids. Using this protocol, >100 primary and metastatic BC organoid lines were generated, broadly recapitulating the diversity of the disease. BC organoid morphologies typically matched the histopathology, hormone receptor status, and HER2 status of the original tumor. DNA copy number variations as well as sequence changes were consistent within tumor-organoid pairs and largely retained even after extended passaging. BC organoids furthermore populated all major gene-expression-based classification groups and allowed in vitro drug screens that were consistent with in vivo xeno-transplantations and patient response. This study describes a representative collection of well-characterized BC organoids available for cancer research and drug development, as well as a strategy to assess in vitro drug response in a personalized fashion.
PY - 2018
SP - 373
EP - 386.e10
T2 - Cell
TI - A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
VL - 172
SN - 1097-4172
ER -